Retatrutide

Technical specifications

Molecular weight

~4,731 Da

Sequence

Synthetic peptide of 39 modified amino acids

Format

Sterile lyophilized

Content

10 mg per vial

Purity

≥99% verified by HPLC in batch CoA

Identity

Confirmed by mass spectrometry (MS)

Storage

Batch traceability and thermal chain documentation

Endotoxins (LAL)

< 5 EU/mg

Water content (Karl Fischer)

< 6%

Amino acid analysis

Composition confirmed by acid hydrolysis

About Retatrutide 10 mg

Research applications

Retatrutide acts simultaneously on three well-characterized G protein-coupled receptors in endocrinological literature: GIP, GLP-1, and the Glucagon receptor [1]. In preclinical models, combined activation of the first two is associated with effects on satiety, insulin sensitivity, and energy expenditure, while the glucagon component distinguishes Retatrutide from classical dual agonists by engaging hepatic lipolysis as an additional mechanism. The peptide structure includes non-canonical amino acid modifications and conjugation with a fatty acid to extend the plasma half-life observed in pharmacokinetic studies. The specific experimental application is the responsibility of the receiving lab and its authorized institutional SOP.

Storage and handling

Sealed vial: store protected from light, humidity, and prolonged air exposure per the batch documentation. Once the experimental solution is prepared, keep refrigerated under documented conditions when the lab protocol requires it; record the preparation date, diluent used, and workstation conditions. Stability of the prepared solution depends on the batch-specific CoA, the diluent, aseptic technique, and the research protocol. Discard the material at any sign of turbidity, suspended particles, or any color change from the initial observation.

Scientific references

1. [1]Coskun T et al. LY3437943, a novel triple GIP/GLP-1/glucagon receptor agonist. Cell Metabolism 2022; 34(9):1234–1247. View source on PubMed →
2. [2]ClinicalTrials.gov — Registered studies for the clinical development of retatrutide. View registry →

Frequently asked questions

• What's included in the Retatrutide 10 mg vial?+

  A sterile lyophilized vial containing Retatrutide 10 mg (LY3437943, synthetic peptide of 39 modified amino acids), shipped with the batch-specific Certificate of Analysis (CoA) — the batch number on the vial is auditable against the independent analytical lab.

• What purity is guaranteed?+

  ≥99% verified by reverse-phase HPLC with a full chromatogram in the CoA. Identity is confirmed by mass spectrometry, and endotoxin (LAL), water content (Karl Fischer), and amino-acid profile controls are also reported.

• What makes Retatrutide unique compared to other incretin agonists?+

  It is a triple agonist at GIP, GLP-1, and the Glucagon receptor. Initial characterization was published by Coskun and colleagues in Cell Metabolism (2022); the glucagon component distinguishes it from classical dual agonists in preclinical metabolic research programs.

• How should the sealed vial be stored?+

  Store protected from light, humidity, and prolonged air exposure per the batch documentation. Stability of the prepared solution depends on the batch-specific CoA, the diluent, aseptic technique, and the lab's institutional SOP.

• Is it legal in Mexico?+

  Yes, as a scientific research compound for experimental in vitro use. It is not a medication, supplement, or consumer product, and it is not approved by COFEPRIS for those uses.

• How long does shipping take, and is there free shipping?+

  1–4 business days depending on destination within Mexico (1–2 north, 2–3 center, 3–4 south) via Estafeta, FedEx, or DHL. Free shipping on orders over $2,000 MXN. We do not ship internationally.